JP2008532925A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008532925A5 JP2008532925A5 JP2007543471A JP2007543471A JP2008532925A5 JP 2008532925 A5 JP2008532925 A5 JP 2008532925A5 JP 2007543471 A JP2007543471 A JP 2007543471A JP 2007543471 A JP2007543471 A JP 2007543471A JP 2008532925 A5 JP2008532925 A5 JP 2008532925A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- indazol
- dihydro
- chromen
- ylurea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 89
- 150000001875 compounds Chemical class 0.000 claims 41
- 125000001424 substituent group Chemical group 0.000 claims 18
- 125000001188 haloalkyl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000003342 alkenyl group Chemical group 0.000 claims 14
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- -1 —OR c Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- LNRLQTQYVBBJBO-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[7-(trifluoromethyl)-3,4-dihydro-2h-chromen-4-yl]urea Chemical compound C1COC2=CC(C(F)(F)F)=CC=C2C1NC(=O)NC1=CC=CC2=C1C=NN2 LNRLQTQYVBBJBO-UHFFFAOYSA-N 0.000 claims 3
- JUSPWOFSXJZIOC-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[[1-[[3-(trifluoromethyl)phenyl]methyl]-3,4-dihydro-2h-quinolin-2-yl]methyl]urea Chemical compound FC(F)(F)C1=CC=CC(CN2C3=CC=CC=C3CCC2CNC(=O)NC=2C=3C=NNC=3C=CC=2)=C1 JUSPWOFSXJZIOC-UHFFFAOYSA-N 0.000 claims 3
- FGVFFUSBPJFGCF-UHFFFAOYSA-N 1-(8-tert-butyl-3,4-dihydro-2h-chromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C1COC=2C(C(C)(C)C)=CC=CC=2C1NC(=O)NC1=CC=CC2=C1C=NN2 FGVFFUSBPJFGCF-UHFFFAOYSA-N 0.000 claims 3
- FAWFVJIDGASJLP-UHFFFAOYSA-N 1-[(1-benzyl-3,4-dihydro-2h-quinolin-2-yl)methyl]-3-(1h-indazol-4-yl)urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NCC1CCC2=CC=CC=C2N1CC1=CC=CC=C1 FAWFVJIDGASJLP-UHFFFAOYSA-N 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- MASAFVZAJXRZCN-UHFFFAOYSA-N 1-(7-tert-butyl-3,4-dihydro-2h-chromen-4-yl)-3-(3-methylisoquinolin-5-yl)urea Chemical compound C1COC2=CC(C(C)(C)C)=CC=C2C1NC(=O)NC1=C2C=C(C)N=CC2=CC=C1 MASAFVZAJXRZCN-UHFFFAOYSA-N 0.000 claims 2
- FDAPTCFAZHVYLK-UHFFFAOYSA-N 1-isoquinolin-5-yl-3-[7-(trifluoromethyl)-3,4-dihydro-2h-chromen-4-yl]urea Chemical compound N1=CC=C2C(NC(=O)NC3C4=CC=C(C=C4OCC3)C(F)(F)F)=CC=CC2=C1 FDAPTCFAZHVYLK-UHFFFAOYSA-N 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- NPRMHFLQUOEODW-UHFFFAOYSA-N OC(=O)n1ncc2c(NC(=O)NC3CN(Cc4ccccc4)c4cc(F)ccc4C3)cccc12 Chemical compound OC(=O)n1ncc2c(NC(=O)NC3CN(Cc4ccccc4)c4cc(F)ccc4C3)cccc12 NPRMHFLQUOEODW-UHFFFAOYSA-N 0.000 claims 2
- 108010025083 TRPV1 receptor Proteins 0.000 claims 2
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 230000003349 osteoarthritic effect Effects 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- YHBYJDDRADGNLJ-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinolin-2-ylmethylurea Chemical compound N1C(CCC2=CC=CC=C12)CNC(N)=O YHBYJDDRADGNLJ-UHFFFAOYSA-N 0.000 claims 1
- FGXCGGVCKKUACY-UHFFFAOYSA-N 1-(1-benzyl-2,3,4,5-tetrahydro-1-benzazepin-5-yl)-3-(1h-indazol-4-yl)urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NC(C1=CC=CC=C11)CCCN1CC1=CC=CC=C1 FGXCGGVCKKUACY-UHFFFAOYSA-N 0.000 claims 1
- JMWGHUKAPWWMPG-UHFFFAOYSA-N 1-(1-benzyl-3,4-dihydro-2h-quinolin-3-yl)-3-(1h-indazol-4-yl)urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NC(CC1=CC=CC=C11)CN1CC1=CC=CC=C1 JMWGHUKAPWWMPG-UHFFFAOYSA-N 0.000 claims 1
- CVNOORHKMWKCEI-UHFFFAOYSA-N 1-(1-benzyl-3,4-dihydro-2h-quinolin-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NC(C1=CC=CC=C11)CCN1CC1=CC=CC=C1 CVNOORHKMWKCEI-UHFFFAOYSA-N 0.000 claims 1
- FCWIBYQHRCBDSA-UHFFFAOYSA-N 1-(1-benzyl-6-fluoro-3,4-dihydro-2h-quinolin-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C1CC(NC(=O)NC=2C=3C=NNC=3C=CC=2)C2=CC(F)=CC=C2N1CC1=CC=CC=C1 FCWIBYQHRCBDSA-UHFFFAOYSA-N 0.000 claims 1
- AYMSYYHWAONOKI-UHFFFAOYSA-N 1-(1-benzyl-6-methoxy-3,4-dihydro-2h-quinolin-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C1CC(NC(=O)NC=2C=3C=NNC=3C=CC=2)C2=CC(OC)=CC=C2N1CC1=CC=CC=C1 AYMSYYHWAONOKI-UHFFFAOYSA-N 0.000 claims 1
- LNCRGVMWIDSWDZ-UHFFFAOYSA-N 1-(1-benzyl-6-tert-butyl-3,4-dihydro-2h-quinolin-3-yl)-3-(1h-indazol-4-yl)urea Chemical compound C1C(NC(=O)NC=2C=3C=NNC=3C=CC=2)CC2=CC(C(C)(C)C)=CC=C2N1CC1=CC=CC=C1 LNCRGVMWIDSWDZ-UHFFFAOYSA-N 0.000 claims 1
- SFXDORUIZFRXSG-UHFFFAOYSA-N 1-(1-benzyl-6-tert-butyl-3,4-dihydro-2h-quinolin-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C1CC(NC(=O)NC=2C=3C=NNC=3C=CC=2)C2=CC(C(C)(C)C)=CC=C2N1CC1=CC=CC=C1 SFXDORUIZFRXSG-UHFFFAOYSA-N 0.000 claims 1
- BTIBLCUSSWNUOC-UHFFFAOYSA-N 1-(1-benzyl-7-fluoro-3,4-dihydro-2h-quinolin-3-yl)-3-(1h-indazol-4-yl)urea Chemical compound C12=CC(F)=CC=C2CC(NC(=O)NC=2C=3C=NNC=3C=CC=2)CN1CC1=CC=CC=C1 BTIBLCUSSWNUOC-UHFFFAOYSA-N 0.000 claims 1
- JTXYTPNMHVUMPB-UHFFFAOYSA-N 1-(1-ethylindazol-4-yl)-3-(7-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl)urea Chemical compound C1C(C)(C)OC2=CC(F)=CC=C2C1NC(=O)NC1=C2C=NN(CC)C2=CC=C1 JTXYTPNMHVUMPB-UHFFFAOYSA-N 0.000 claims 1
- ADEBLLBBBCQCDI-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-(1-methyl-3,4-dihydro-2h-quinolin-4-yl)urea Chemical compound C12=CC=CC=C2N(C)CCC1NC(=O)NC1=CC=CC2=C1C=NN2 ADEBLLBBBCQCDI-UHFFFAOYSA-N 0.000 claims 1
- MPTPURFMBQGHAG-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-(2,2,8-trimethyl-3,4-dihydrochromen-4-yl)urea Chemical compound C1C(C)(C)OC=2C(C)=CC=CC=2C1NC(=O)NC1=CC=CC2=C1C=NN2 MPTPURFMBQGHAG-UHFFFAOYSA-N 0.000 claims 1
- VKINZKIRILCDFD-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-(6-methyl-3,4-dihydro-2h-chromen-4-yl)urea Chemical compound C12=CC(C)=CC=C2OCCC1NC(=O)NC1=CC=CC2=C1C=NN2 VKINZKIRILCDFD-UHFFFAOYSA-N 0.000 claims 1
- TXYBMMZLKHMZII-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-(7-methoxy-2,2,8-trimethyl-3,4-dihydrochromen-4-yl)urea Chemical compound C1C(C)(C)OC2=C(C)C(OC)=CC=C2C1NC(=O)NC1=CC=CC2=C1C=NN2 TXYBMMZLKHMZII-UHFFFAOYSA-N 0.000 claims 1
- PVYNJQODFKXXFR-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-(7-methoxy-2,2-dimethyl-3,4-dihydrochromen-4-yl)urea Chemical compound C1C(C)(C)OC2=CC(OC)=CC=C2C1NC(=O)NC1=CC=CC2=C1C=NN2 PVYNJQODFKXXFR-UHFFFAOYSA-N 0.000 claims 1
- MCCWMGNDQBQPEC-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-(7-methoxy-2,2-dimethyl-8-propyl-3,4-dihydrochromen-4-yl)urea Chemical compound C1C(C)(C)OC=2C(CCC)=C(OC)C=CC=2C1NC(=O)NC1=CC=CC2=C1C=NN2 MCCWMGNDQBQPEC-UHFFFAOYSA-N 0.000 claims 1
- WXWCVKMJZSOKCO-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-(7-methoxy-2-phenyl-3,4-dihydro-2h-chromen-4-yl)urea Chemical compound O1C2=CC(OC)=CC=C2C(NC(=O)NC=2C=3C=NNC=3C=CC=2)CC1C1=CC=CC=C1 WXWCVKMJZSOKCO-UHFFFAOYSA-N 0.000 claims 1
- DRKFVZNNQBSDBF-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-(8-morpholin-4-yl-3,4-dihydro-2h-chromen-4-yl)urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NC1CCOC2=C1C=CC=C2N1CCOCC1 DRKFVZNNQBSDBF-UHFFFAOYSA-N 0.000 claims 1
- BWUZDTXKQFBCBM-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-(8-piperidin-1-yl-3,4-dihydro-2h-chromen-4-yl)urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NC1CCOC2=C1C=CC=C2N1CCCCC1 BWUZDTXKQFBCBM-UHFFFAOYSA-N 0.000 claims 1
- OSMLRKGCJFBTSO-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[(1-propyl-3,4-dihydro-2h-quinolin-2-yl)methyl]urea Chemical compound C1CC2=CC=CC=C2N(CCC)C1CNC(=O)NC1=CC=CC2=C1C=NN2 OSMLRKGCJFBTSO-UHFFFAOYSA-N 0.000 claims 1
- POLTYCBJHGMTBT-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[1-(3-phenylpropyl)-7-(trifluoromethyl)-3,4-dihydro-2h-quinolin-3-yl]urea Chemical compound C12=CC(C(F)(F)F)=CC=C2CC(NC(=O)NC=2C=3C=NNC=3C=CC=2)CN1CCCC1=CC=CC=C1 POLTYCBJHGMTBT-UHFFFAOYSA-N 0.000 claims 1
- OAGOFYGHRQNIDL-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[1-[[3-(trifluoromethyl)phenyl]methyl]-3,4-dihydro-2h-quinolin-3-yl]urea Chemical compound FC(F)(F)C1=CC=CC(CN2C3=CC=CC=C3CC(C2)NC(=O)NC=2C=3C=NNC=3C=CC=2)=C1 OAGOFYGHRQNIDL-UHFFFAOYSA-N 0.000 claims 1
- ITFPFVZGWFKJMG-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[1-methyl-7-(trifluoromethyl)-3,4-dihydro-2h-quinolin-4-yl]urea Chemical compound C12=CC=C(C(F)(F)F)C=C2N(C)CCC1NC(=O)NC1=CC=CC2=C1C=NN2 ITFPFVZGWFKJMG-UHFFFAOYSA-N 0.000 claims 1
- CHVBTEZXWRYVOG-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[7-(trifluoromethoxy)-3,4-dihydro-2h-chromen-4-yl]urea Chemical compound C1COC2=CC(OC(F)(F)F)=CC=C2C1NC(=O)NC1=CC=CC2=C1C=NN2 CHVBTEZXWRYVOG-UHFFFAOYSA-N 0.000 claims 1
- XKXJVTYDGSUSKI-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[8-(trifluoromethoxy)-3,4-dihydro-2h-chromen-4-yl]urea Chemical compound C1COC=2C(OC(F)(F)F)=CC=CC=2C1NC(=O)NC1=CC=CC2=C1C=NN2 XKXJVTYDGSUSKI-UHFFFAOYSA-N 0.000 claims 1
- CRCCQJDITKRXDH-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[8-(trifluoromethyl)-3,4-dihydro-2h-chromen-4-yl]urea Chemical compound C1COC=2C(C(F)(F)F)=CC=CC=2C1NC(=O)NC1=CC=CC2=C1C=NN2 CRCCQJDITKRXDH-UHFFFAOYSA-N 0.000 claims 1
- YUYRDRHVSPICBY-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[[1-(2-phenylethyl)-3,4-dihydro-2h-quinolin-2-yl]methyl]urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NCC1CCC2=CC=CC=C2N1CCC1=CC=CC=C1 YUYRDRHVSPICBY-UHFFFAOYSA-N 0.000 claims 1
- BSWNUMOXKJBAEC-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[[1-(3-phenylpropyl)-3,4-dihydro-2h-quinolin-2-yl]methyl]urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NCC1CCC2=CC=CC=C2N1CCCC1=CC=CC=C1 BSWNUMOXKJBAEC-UHFFFAOYSA-N 0.000 claims 1
- HHBRVBWBJRXBFF-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[[1-(pyridin-2-ylmethyl)-3,4-dihydro-2h-quinolin-2-yl]methyl]urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NCC1CCC2=CC=CC=C2N1CC1=CC=CC=N1 HHBRVBWBJRXBFF-UHFFFAOYSA-N 0.000 claims 1
- NLELPKGKSYREII-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[[1-(trifluoromethylsulfonyl)-3,4-dihydro-2h-quinolin-2-yl]methyl]urea Chemical compound C1CC2=CC=CC=C2N(S(=O)(=O)C(F)(F)F)C1CNC(=O)NC1=CC=CC2=C1C=NN2 NLELPKGKSYREII-UHFFFAOYSA-N 0.000 claims 1
- NHWCANILDANDRT-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[[1-[[2-(trifluoromethyl)phenyl]methyl]-3,4-dihydro-2h-quinolin-2-yl]methyl]urea Chemical compound FC(F)(F)C1=CC=CC=C1CN1C2=CC=CC=C2CCC1CNC(=O)NC1=CC=CC2=C1C=NN2 NHWCANILDANDRT-UHFFFAOYSA-N 0.000 claims 1
- UBUYYVLKHWWBOU-UHFFFAOYSA-N 1-(1h-indazol-4-yl)-3-[[1-[[4-(trifluoromethyl)phenyl]methyl]-3,4-dihydro-2h-quinolin-2-yl]methyl]urea Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1C2=CC=CC=C2CCC1CNC(=O)NC1=CC=CC2=C1C=NN2 UBUYYVLKHWWBOU-UHFFFAOYSA-N 0.000 claims 1
- IDVNTJAGOBONHF-UHFFFAOYSA-N 1-(2,2-dibutyl-7-fluoro-3,4-dihydrochromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C12=CC=C(F)C=C2OC(CCCC)(CCCC)CC1NC(=O)NC1=CC=CC2=C1C=NN2 IDVNTJAGOBONHF-UHFFFAOYSA-N 0.000 claims 1
- MMSMTMQGZFFWET-UHFFFAOYSA-N 1-(2,2-diethyl-7-fluoro-3,4-dihydrochromen-4-yl)-3-(1-methylindazol-4-yl)urea Chemical compound C12=CC=C(F)C=C2OC(CC)(CC)CC1NC(=O)NC1=CC=CC2=C1C=NN2C MMSMTMQGZFFWET-UHFFFAOYSA-N 0.000 claims 1
- IHTTUOYEOCHAHS-UHFFFAOYSA-N 1-(2,2-diethyl-7-fluoro-3,4-dihydrochromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C12=CC=C(F)C=C2OC(CC)(CC)CC1NC(=O)NC1=CC=CC2=C1C=NN2 IHTTUOYEOCHAHS-UHFFFAOYSA-N 0.000 claims 1
- FOXQNSKEGIEOEW-UHFFFAOYSA-N 1-(2,2-dimethyl-3,4-dihydrochromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C12=CC=CC=C2OC(C)(C)CC1NC(=O)NC1=CC=CC2=C1C=NN2 FOXQNSKEGIEOEW-UHFFFAOYSA-N 0.000 claims 1
- GYTCPWPDOHESAY-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3-(1h-indazol-4-yl)urea Chemical compound C1OC2=CC=CC=C2OC1CNC(=O)NC1=CC=CC2=C1C=NN2 GYTCPWPDOHESAY-UHFFFAOYSA-N 0.000 claims 1
- UMVFAVGJJHKXRM-UHFFFAOYSA-N 1-(2,3-dihydro-1-benzofuran-2-ylmethyl)-3-(1h-indazol-4-yl)urea Chemical compound C1C2=CC=CC=C2OC1CNC(=O)NC1=CC=CC2=C1C=NN2 UMVFAVGJJHKXRM-UHFFFAOYSA-N 0.000 claims 1
- HNYUSGJGGMMXFW-UHFFFAOYSA-N 1-(2-ethylindazol-4-yl)-3-(7-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl)urea Chemical compound C1C(C)(C)OC2=CC(F)=CC=C2C1NC(=O)NC1=CC=CC2=NN(CC)C=C21 HNYUSGJGGMMXFW-UHFFFAOYSA-N 0.000 claims 1
- BUGPFPKBJAUVIJ-UHFFFAOYSA-N 1-(2-tert-butyl-7-fluoro-3,4-dihydro-2h-chromen-4-yl)-3-(1-methylindazol-4-yl)urea Chemical compound C1C(C(C)(C)C)OC2=CC(F)=CC=C2C1NC(=O)NC1=C2C=NN(C)C2=CC=C1 BUGPFPKBJAUVIJ-UHFFFAOYSA-N 0.000 claims 1
- DWCDXFFPOOYDNU-UHFFFAOYSA-N 1-(2-tert-butyl-7-fluoro-3,4-dihydro-2h-chromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C12=CC=C(F)C=C2OC(C(C)(C)C)CC1NC(=O)NC1=CC=CC2=C1C=NN2 DWCDXFFPOOYDNU-UHFFFAOYSA-N 0.000 claims 1
- NADXNPJWRMMDRM-UHFFFAOYSA-N 1-(3,4-dihydro-2h-1,4-benzoxazin-2-ylmethyl)-3-(1h-indazol-4-yl)urea Chemical compound C1NC2=CC=CC=C2OC1CNC(=O)NC1=CC=CC2=C1C=NN2 NADXNPJWRMMDRM-UHFFFAOYSA-N 0.000 claims 1
- JPNFDXYNTFZROK-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-2-ylmethyl)-3-(1h-indazol-4-yl)urea Chemical compound C1CC2=CC=CC=C2OC1CNC(=O)NC1=CC=CC2=C1C=NN2 JPNFDXYNTFZROK-UHFFFAOYSA-N 0.000 claims 1
- KNVHRZOGCSRXTA-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-3-yl)-3-isoquinolin-5-ylurea Chemical compound N1=CC=C2C(NC(NC3CC4=CC=CC=C4OC3)=O)=CC=CC2=C1 KNVHRZOGCSRXTA-UHFFFAOYSA-N 0.000 claims 1
- JCIVLZGCUOMREG-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C1COC2=CC=CC=C2C1NC(=O)NC1=CC=CC2=C1C=NN2 JCIVLZGCUOMREG-UHFFFAOYSA-N 0.000 claims 1
- LRSVHBILTQOERP-UHFFFAOYSA-N 1-(6-chloro-7-methyl-3,4-dihydro-2h-chromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C1=2C=C(Cl)C(C)=CC=2OCCC1NC(=O)NC1=CC=CC2=C1C=NN2 LRSVHBILTQOERP-UHFFFAOYSA-N 0.000 claims 1
- VQJCSJIAIWNJSO-UHFFFAOYSA-N 1-(6-chloro-7-methyl-3,4-dihydro-2h-chromen-4-yl)-3-isoquinolin-5-ylurea Chemical compound N1=CC=C2C(NC(=O)NC3CCOC=4C=C(C(=CC=43)Cl)C)=CC=CC2=C1 VQJCSJIAIWNJSO-UHFFFAOYSA-N 0.000 claims 1
- MJMAJBXEOLLLDS-UHFFFAOYSA-N 1-(6-chloro-7-methyl-3,4-dihydro-2h-chromen-4-yl)-3-quinolin-5-ylurea Chemical compound C1=CC=C2C(NC(=O)NC3CCOC=4C=C(C(=CC=43)Cl)C)=CC=CC2=N1 MJMAJBXEOLLLDS-UHFFFAOYSA-N 0.000 claims 1
- GMGYJBTXGBSQGB-UHFFFAOYSA-N 1-(6-fluoro-2-methyl-3,4-dihydro-2h-chromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C12=CC(F)=CC=C2OC(C)CC1NC(=O)NC1=CC=CC2=C1C=NN2 GMGYJBTXGBSQGB-UHFFFAOYSA-N 0.000 claims 1
- WDXRHDBNVFLNOA-UHFFFAOYSA-N 1-(6-fluoro-3,4-dihydro-2h-chromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C12=CC(F)=CC=C2OCCC1NC(=O)NC1=CC=CC2=C1C=NN2 WDXRHDBNVFLNOA-UHFFFAOYSA-N 0.000 claims 1
- YIDXTTBTOVGXQW-UHFFFAOYSA-N 1-(6-fluoro-3,4-dihydro-2h-chromen-4-yl)-3-isoquinolin-5-ylurea Chemical compound N1=CC=C2C(NC(=O)NC3CCOC4=CC=C(C=C43)F)=CC=CC2=C1 YIDXTTBTOVGXQW-UHFFFAOYSA-N 0.000 claims 1
- QWWCSSSULKYTLF-UHFFFAOYSA-N 1-(6-fluoro-3,4-dihydro-2h-chromen-4-yl)-3-quinolin-5-ylurea Chemical compound C1=CC=C2C(NC(=O)NC3CCOC4=CC=C(C=C43)F)=CC=CC2=N1 QWWCSSSULKYTLF-UHFFFAOYSA-N 0.000 claims 1
- JJAHUIPYJLEKHW-UHFFFAOYSA-N 1-(6-methyl-3,4-dihydro-2h-chromen-4-yl)-3-(3-methylisoquinolin-5-yl)urea Chemical compound N1=C(C)C=C2C(NC(=O)NC3CCOC4=CC=C(C=C43)C)=CC=CC2=C1 JJAHUIPYJLEKHW-UHFFFAOYSA-N 0.000 claims 1
- OGYNVNYKCFZCQL-UHFFFAOYSA-N 1-(6-methyl-3,4-dihydro-2h-chromen-4-yl)-3-quinolin-5-ylurea Chemical compound C1=CC=C2C(NC(=O)NC3CCOC4=CC=C(C=C43)C)=CC=CC2=N1 OGYNVNYKCFZCQL-UHFFFAOYSA-N 0.000 claims 1
- AAKPNNJMZRMCHW-UHFFFAOYSA-N 1-(6-methyl-3,4-dihydro-2h-chromen-4-yl)-3-quinolin-8-ylurea Chemical compound C1=CN=C2C(NC(=O)NC3CCOC4=CC=C(C=C43)C)=CC=CC2=C1 AAKPNNJMZRMCHW-UHFFFAOYSA-N 0.000 claims 1
- WFZDKUJYZFGQSX-UHFFFAOYSA-N 1-(7,8-difluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C12=CC=C(F)C(F)=C2OC(C)(C)CC1NC(=O)NC1=CC=CC2=C1C=NN2 WFZDKUJYZFGQSX-UHFFFAOYSA-N 0.000 claims 1
- QKGZZEPGSFJYIP-UHFFFAOYSA-N 1-(7,8-difluoro-3,4-dihydro-2h-chromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C1COC2=C(F)C(F)=CC=C2C1NC(=O)NC1=CC=CC2=C1C=NN2 QKGZZEPGSFJYIP-UHFFFAOYSA-N 0.000 claims 1
- AWVYCAFGYUVHBP-UHFFFAOYSA-N 1-(7-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C12=CC=C(F)C=C2OC(C)(C)CC1NC(=O)NC1=CC=CC2=C1C=NN2 AWVYCAFGYUVHBP-UHFFFAOYSA-N 0.000 claims 1
- CBUXRBCQRSNJTJ-UHFFFAOYSA-N 1-(7-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl)-3-[1-(2-methoxyethyl)indazol-4-yl]urea Chemical compound C1C(C)(C)OC2=CC(F)=CC=C2C1NC(=O)NC1=C2C=NN(CCOC)C2=CC=C1 CBUXRBCQRSNJTJ-UHFFFAOYSA-N 0.000 claims 1
- HZCWTWPZWYWLGJ-UHFFFAOYSA-N 1-(7-fluoro-2,2-dipropyl-3,4-dihydrochromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C12=CC=C(F)C=C2OC(CCC)(CCC)CC1NC(=O)NC1=CC=CC2=C1C=NN2 HZCWTWPZWYWLGJ-UHFFFAOYSA-N 0.000 claims 1
- FZUXQDIXBAAZHO-UHFFFAOYSA-N 1-(7-tert-butyl-2,2-dimethyl-3,4-dihydrochromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C1C(C)(C)OC2=CC(C(C)(C)C)=CC=C2C1NC(=O)NC1=CC=CC2=C1C=NN2 FZUXQDIXBAAZHO-UHFFFAOYSA-N 0.000 claims 1
- OMIRFNXDMYBLLF-UHFFFAOYSA-N 1-(7-tert-butyl-3,4-dihydro-2h-chromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C1COC2=CC(C(C)(C)C)=CC=C2C1NC(=O)NC1=CC=CC2=C1C=NN2 OMIRFNXDMYBLLF-UHFFFAOYSA-N 0.000 claims 1
- PFLVWBBMCOHXBI-UHFFFAOYSA-N 1-(7-tert-butyl-3,4-dihydro-2h-chromen-4-yl)-3-quinolin-5-ylurea Chemical compound C1=CC=C2C(NC(=O)NC3C4=CC=C(C=C4OCC3)C(C)(C)C)=CC=CC2=N1 PFLVWBBMCOHXBI-UHFFFAOYSA-N 0.000 claims 1
- CJHZOBWTVLHNPM-UHFFFAOYSA-N 1-(7-tert-butyl-3,4-dihydro-2h-chromen-4-yl)-3-quinolin-8-ylurea Chemical compound C1=CN=C2C(NC(=O)NC3C4=CC=C(C=C4OCC3)C(C)(C)C)=CC=CC2=C1 CJHZOBWTVLHNPM-UHFFFAOYSA-N 0.000 claims 1
- NVMRZBHUMZFLEI-UHFFFAOYSA-N 1-(8-cyclohexyl-3,4-dihydro-2h-chromen-4-yl)-3-(1h-indazol-4-yl)urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NC(C1=CC=C2)CCOC1=C2C1CCCCC1 NVMRZBHUMZFLEI-UHFFFAOYSA-N 0.000 claims 1
- ACEHCQYIBFFPON-UHFFFAOYSA-N 1-[(1-benzyl-2,3-dihydroindol-2-yl)methyl]-3-(1h-indazol-4-yl)urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NCC1CC2=CC=CC=C2N1CC1=CC=CC=C1 ACEHCQYIBFFPON-UHFFFAOYSA-N 0.000 claims 1
- VJGKAUKWFSBMMV-UHFFFAOYSA-N 1-[(1-benzyl-3,4-dihydro-2h-quinolin-2-yl)methyl]-3-isoquinolin-5-ylurea Chemical compound C=1C=CC2=CN=CC=C2C=1NC(=O)NCC1CCC2=CC=CC=C2N1CC1=CC=CC=C1 VJGKAUKWFSBMMV-UHFFFAOYSA-N 0.000 claims 1
- YBHFLNPHBYUHSF-UHFFFAOYSA-N 1-[(1-benzyl-6-fluoro-3,4-dihydro-2h-quinolin-2-yl)methyl]-3-(1h-indazol-4-yl)urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NCC1CCC2=CC(F)=CC=C2N1CC1=CC=CC=C1 YBHFLNPHBYUHSF-UHFFFAOYSA-N 0.000 claims 1
- WFTHPKJLXNIKMX-UHFFFAOYSA-N 1-[(4-benzyl-2,3-dihydro-1,4-benzoxazin-2-yl)methyl]-3-(1h-indazol-4-yl)urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NCC(OC1=CC=CC=C11)CN1CC1=CC=CC=C1 WFTHPKJLXNIKMX-UHFFFAOYSA-N 0.000 claims 1
- XFXAXIXVJKIEKT-UHFFFAOYSA-N 1-[1-(cyclohexylmethyl)-6-methoxy-3,4-dihydro-2h-quinolin-4-yl]-3-(1h-indazol-4-yl)urea Chemical compound C1CC(NC(=O)NC=2C=3C=NNC=3C=CC=2)C2=CC(OC)=CC=C2N1CC1CCCCC1 XFXAXIXVJKIEKT-UHFFFAOYSA-N 0.000 claims 1
- QMDUKTOFGWQLLH-UHFFFAOYSA-N 1-[1-benzyl-7-(trifluoromethoxy)-3,4-dihydro-2h-quinolin-3-yl]-3-(1h-indazol-4-yl)urea Chemical compound C12=CC(OC(F)(F)F)=CC=C2CC(NC(=O)NC=2C=3C=NNC=3C=CC=2)CN1CC1=CC=CC=C1 QMDUKTOFGWQLLH-UHFFFAOYSA-N 0.000 claims 1
- RMURSGKDSRERHP-UHFFFAOYSA-N 1-[7-(3,3-dimethylbutyl)-1-methyl-3,4-dihydro-2h-quinolin-4-yl]-3-(1h-indazol-4-yl)urea Chemical compound C12=CC=C(CCC(C)(C)C)C=C2N(C)CCC1NC(=O)NC1=CC=CC2=C1C=NN2 RMURSGKDSRERHP-UHFFFAOYSA-N 0.000 claims 1
- ILZMLSPSCRIAII-UHFFFAOYSA-N 1-[8-chloro-1-(3-methylbutyl)-3,4-dihydro-2h-quinolin-4-yl]-3-(1h-indazol-4-yl)urea Chemical compound C12=CC=CC(Cl)=C2N(CCC(C)C)CCC1NC(=O)NC1=CC=CC2=C1C=NN2 ILZMLSPSCRIAII-UHFFFAOYSA-N 0.000 claims 1
- DDMMMYOZYVTAEO-UHFFFAOYSA-N 1-[8-chloro-7-(trifluoromethyl)-3,4-dihydro-2h-chromen-4-yl]-3-(1h-indazol-4-yl)urea Chemical compound C1COC2=C(Cl)C(C(F)(F)F)=CC=C2C1NC(=O)NC1=CC=CC2=C1C=NN2 DDMMMYOZYVTAEO-UHFFFAOYSA-N 0.000 claims 1
- WWNNLZBHVPFHOE-UHFFFAOYSA-N 1-[8-fluoro-7-(trifluoromethyl)-3,4-dihydro-2h-chromen-4-yl]-3-(1h-indazol-4-yl)urea Chemical compound C12=CC=C(C(F)(F)F)C(F)=C2OCCC1NC(=O)NC1=CC=CC2=C1C=NN2 WWNNLZBHVPFHOE-UHFFFAOYSA-N 0.000 claims 1
- OYIBXDLVXGTAGZ-UHFFFAOYSA-N 1-[[1-(cyclohexylmethyl)-3,4-dihydro-2h-quinolin-2-yl]methyl]-3-(1h-indazol-4-yl)urea Chemical compound C=1C=CC=2NN=CC=2C=1NC(=O)NCC1CCC2=CC=CC=C2N1CC1CCCCC1 OYIBXDLVXGTAGZ-UHFFFAOYSA-N 0.000 claims 1
- PHHRDEAESPQCIV-UHFFFAOYSA-N 1-isoquinolin-5-yl-3-(6-methyl-3,4-dihydro-2h-chromen-4-yl)urea Chemical compound N1=CC=C2C(NC(=O)NC3CCOC4=CC=C(C=C43)C)=CC=CC2=C1 PHHRDEAESPQCIV-UHFFFAOYSA-N 0.000 claims 1
- HQUQCIBCUMNQAA-UHFFFAOYSA-N 1-isoquinolin-5-yl-3-(8-piperidin-1-yl-3,4-dihydro-2h-chromen-4-yl)urea Chemical compound C=1C=CC2=CN=CC=C2C=1NC(=O)NC1CCOC2=C1C=CC=C2N1CCCCC1 HQUQCIBCUMNQAA-UHFFFAOYSA-N 0.000 claims 1
- OQDKWISVFFMYFI-UHFFFAOYSA-N 1-isoquinolin-5-yl-3-[[1-(2-phenylethyl)-3,4-dihydro-2h-quinolin-2-yl]methyl]urea Chemical compound C=1C=CC2=CN=CC=C2C=1NC(=O)NCC1CCC2=CC=CC=C2N1CCC1=CC=CC=C1 OQDKWISVFFMYFI-UHFFFAOYSA-N 0.000 claims 1
- GKMQZGBRJUQYKE-UHFFFAOYSA-N 1-isoquinolin-5-yl-3-[[1-(3-phenylpropyl)-3,4-dihydro-2h-quinolin-2-yl]methyl]urea Chemical compound C=1C=CC2=CN=CC=C2C=1NC(=O)NCC1CCC2=CC=CC=C2N1CCCC1=CC=CC=C1 GKMQZGBRJUQYKE-UHFFFAOYSA-N 0.000 claims 1
- MTVMLXMUFHTONP-UHFFFAOYSA-N 1-quinolin-5-yl-3-[7-(trifluoromethyl)-3,4-dihydro-2h-chromen-4-yl]urea Chemical compound C1=CC=C2C(NC(=O)NC3C4=CC=C(C=C4OCC3)C(F)(F)F)=CC=CC2=N1 MTVMLXMUFHTONP-UHFFFAOYSA-N 0.000 claims 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- CXUNRYHCEDUJFR-UHFFFAOYSA-N 4-[(1-benzyl-6-fluoro-3,4-dihydro-2H-quinolin-2-yl)methylcarbamoylamino]indazole-1-carboxylic acid Chemical compound OC(=O)n1ncc2c(NC(=O)NCC3CCc4cc(F)ccc4N3Cc3ccccc3)cccc12 CXUNRYHCEDUJFR-UHFFFAOYSA-N 0.000 claims 1
- QYXDXMDPKMSVMD-UHFFFAOYSA-N 4-[(1-methyl-3,4-dihydro-2H-quinolin-4-yl)carbamoylamino]indazole-1-carboxylic acid Chemical compound CN1CCC(C2=CC=CC=C21)NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O QYXDXMDPKMSVMD-UHFFFAOYSA-N 0.000 claims 1
- JIUMMHZVDKMBHJ-UHFFFAOYSA-N 4-[(8-tert-butyl-3,4-dihydro-2H-chromen-4-yl)carbamoylamino]indazole-1-carboxylic acid Chemical compound C1COC=2C(C(C)(C)C)=CC=CC=2C1NC(=O)NC1=CC=CC2=C1C=NN2C(O)=O JIUMMHZVDKMBHJ-UHFFFAOYSA-N 0.000 claims 1
- SILBFFLWYYSZDI-UHFFFAOYSA-N 4-[[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]carbamoylamino]indazole-1-carboxylic acid Chemical compound FC(C1=CC=C2C(CCOC2=C1)NC(NC1=C2C=NN(C2=CC=C1)C(=O)O)=O)(F)F SILBFFLWYYSZDI-UHFFFAOYSA-N 0.000 claims 1
- WQLCJNWIGVZEFK-UHFFFAOYSA-N 4-[[8-chloro-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]carbamoylamino]indazole-1-carboxylic acid Chemical compound C1COC2=C(Cl)C(C(F)(F)F)=CC=C2C1NC(=O)NC1=C2C=NN(C(=O)O)C2=CC=C1 WQLCJNWIGVZEFK-UHFFFAOYSA-N 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- RDYNTYNEJFNAME-UHFFFAOYSA-N C1=CC=C2N(C(=O)O)N=CC2=C1NC(=O)NCC1CCC2=CC=CC=C2N1CC1CCCCC1 Chemical compound C1=CC=C2N(C(=O)O)N=CC2=C1NC(=O)NCC1CCC2=CC=CC=C2N1CC1CCCCC1 RDYNTYNEJFNAME-UHFFFAOYSA-N 0.000 claims 1
- XMPXBAZKZOJMIE-UHFFFAOYSA-N C1=CC=C2N(C(=O)O)N=CC2=C1NC(=O)NCC1CCC2=CC=CC=C2N1CCC1=CC=CC=C1 Chemical compound C1=CC=C2N(C(=O)O)N=CC2=C1NC(=O)NCC1CCC2=CC=CC=C2N1CCC1=CC=CC=C1 XMPXBAZKZOJMIE-UHFFFAOYSA-N 0.000 claims 1
- HTGAXNWQUQTHIM-UHFFFAOYSA-N C1=CC=C2N(C(=O)O)N=CC2=C1NC(=O)NCC1CCC2=CC=CC=C2N1CCCC1=CC=CC=C1 Chemical compound C1=CC=C2N(C(=O)O)N=CC2=C1NC(=O)NCC1CCC2=CC=CC=C2N1CCCC1=CC=CC=C1 HTGAXNWQUQTHIM-UHFFFAOYSA-N 0.000 claims 1
- YDITZVQOPOAQNM-UHFFFAOYSA-N C1C(CN(C2=CC=CC=C21)CC3=CC(=CC=C3)C(F)(F)F)NC(=O)NC4=C5C=NN(C5=CC=C4)C(=O)O Chemical compound C1C(CN(C2=CC=CC=C21)CC3=CC(=CC=C3)C(F)(F)F)NC(=O)NC4=C5C=NN(C5=CC=C4)C(=O)O YDITZVQOPOAQNM-UHFFFAOYSA-N 0.000 claims 1
- IFODTBNDKDYEED-UHFFFAOYSA-N C1CCC(CC1)C2=C3C(=CC=C2)C(CCO3)NC(=O)NC4=C5C=NN(C5=CC=C4)C(=O)O Chemical compound C1CCC(CC1)C2=C3C(=CC=C2)C(CCO3)NC(=O)NC4=C5C=NN(C5=CC=C4)C(=O)O IFODTBNDKDYEED-UHFFFAOYSA-N 0.000 claims 1
- RUBVGPYFRZBNGS-UHFFFAOYSA-N C1COC2=C(C1NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O)C=CC(=C2)OC(F)(F)F Chemical compound C1COC2=C(C1NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O)C=CC(=C2)OC(F)(F)F RUBVGPYFRZBNGS-UHFFFAOYSA-N 0.000 claims 1
- ZARUOCZMPYNVCS-UHFFFAOYSA-N C1COC2=C(C1NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O)C=CC(=C2F)C(F)(F)F Chemical compound C1COC2=C(C1NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O)C=CC(=C2F)C(F)(F)F ZARUOCZMPYNVCS-UHFFFAOYSA-N 0.000 claims 1
- BWNOAINPWXFXLX-UHFFFAOYSA-N C1COC2=C(C1NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O)C=CC=C2C(F)(F)F Chemical compound C1COC2=C(C1NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O)C=CC=C2C(F)(F)F BWNOAINPWXFXLX-UHFFFAOYSA-N 0.000 claims 1
- MXVQMDBVKITKDL-UHFFFAOYSA-N C1COC2=C(C1NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O)C=CC=C2N5CCOCC5 Chemical compound C1COC2=C(C1NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O)C=CC=C2N5CCOCC5 MXVQMDBVKITKDL-UHFFFAOYSA-N 0.000 claims 1
- KADYSALHVYAWOY-UHFFFAOYSA-N C1COC2=C(C1NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O)C=CC=C2OC(F)(F)F Chemical compound C1COC2=C(C1NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O)C=CC=C2OC(F)(F)F KADYSALHVYAWOY-UHFFFAOYSA-N 0.000 claims 1
- KJDOKDCKNODPQD-UHFFFAOYSA-N CC(C)(C)C1=CC2=C(C=C1)N(CC(C2)NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O)CC5=CC=CC=C5 Chemical compound CC(C)(C)C1=CC2=C(C=C1)N(CC(C2)NC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O)CC5=CC=CC=C5 KJDOKDCKNODPQD-UHFFFAOYSA-N 0.000 claims 1
- FXRZNNROYUIPRV-UHFFFAOYSA-N CCCN1C(CCC2=CC=CC=C21)CNC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O Chemical compound CCCN1C(CCC2=CC=CC=C21)CNC(=O)NC3=C4C=NN(C4=CC=C3)C(=O)O FXRZNNROYUIPRV-UHFFFAOYSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- DLEWHLXHIXTADD-UHFFFAOYSA-N OC(=O)n1ncc2c(NC(=O)NC3CCOc4c3cccc4N3CCCCC3)cccc12 Chemical compound OC(=O)n1ncc2c(NC(=O)NC3CCOc4c3cccc4N3CCCCC3)cccc12 DLEWHLXHIXTADD-UHFFFAOYSA-N 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 0 C*(*C*=O)N Chemical compound C*(*C*=O)N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63063604P | 2004-11-24 | 2004-11-24 | |
| US60/630,636 | 2004-11-24 | ||
| PCT/US2005/042545 WO2006065484A2 (en) | 2004-11-24 | 2005-11-22 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012003232A Division JP2012111766A (ja) | 2004-11-24 | 2012-01-11 | バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008532925A JP2008532925A (ja) | 2008-08-21 |
| JP2008532925A5 true JP2008532925A5 (enExample) | 2008-10-23 |
| JP4932730B2 JP4932730B2 (ja) | 2012-05-16 |
Family
ID=36588346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543471A Expired - Fee Related JP4932730B2 (ja) | 2004-11-24 | 2005-11-22 | バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用 |
| JP2012003232A Pending JP2012111766A (ja) | 2004-11-24 | 2012-01-11 | バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012003232A Pending JP2012111766A (ja) | 2004-11-24 | 2012-01-11 | バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7812019B2 (enExample) |
| EP (2) | EP1844038A2 (enExample) |
| JP (2) | JP4932730B2 (enExample) |
| KR (2) | KR101250824B1 (enExample) |
| CN (2) | CN102161653A (enExample) |
| AU (1) | AU2005316972B2 (enExample) |
| BR (1) | BRPI0518581A2 (enExample) |
| CA (1) | CA2588909A1 (enExample) |
| IL (1) | IL183321A0 (enExample) |
| MX (1) | MX2007006205A (enExample) |
| NZ (1) | NZ555318A (enExample) |
| TW (1) | TW200633712A (enExample) |
| WO (1) | WO2006065484A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005086331A2 (en) * | 2004-03-02 | 2005-09-15 | Rosemount, Inc. | Process device with improved power generation |
| US8538560B2 (en) | 2004-04-29 | 2013-09-17 | Rosemount Inc. | Wireless power and communication unit for process field devices |
| US8145180B2 (en) * | 2004-05-21 | 2012-03-27 | Rosemount Inc. | Power generation for process devices |
| CN102161653A (zh) * | 2004-11-24 | 2011-08-24 | 雅培制药有限公司 | 抑制香草素受体亚型1(vr1)受体的苯并二氢吡喃基脲化合物及其用途 |
| WO2006078697A1 (en) * | 2005-01-18 | 2006-07-27 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| MX2007013163A (es) * | 2005-04-22 | 2008-01-21 | Wyeth Corp | Derivados de cromano y cromeno y usos de los mismos. |
| KR20080067361A (ko) * | 2005-10-28 | 2008-07-18 | 아보트 러보러터리즈 | Ｔｒｐｖ1 수용체를 억제하는 인다졸 유도체 |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| RU2450006C2 (ru) * | 2006-04-18 | 2012-05-10 | Эбботт Лэборетриз | Антагонисты ванилоидного рецептора подтипа 1(vr1) и их применение |
| US7913566B2 (en) | 2006-05-23 | 2011-03-29 | Rosemount Inc. | Industrial process device utilizing magnetic induction |
| WO2008059339A2 (en) * | 2006-11-13 | 2008-05-22 | Glenmark Pharmaceuticals S.A. | Isoquinoline derivatives as vanilloid receptor modulators |
| CA2672196A1 (en) * | 2006-12-20 | 2008-07-03 | Abbott Laboratories | Antagonists of the trpv1 receptor and uses thereof |
| WO2008110863A1 (en) * | 2007-03-15 | 2008-09-18 | Glenmark Pharmaceuticals S.A. | Indazole derivatives and their use as vanilloid receptor ligands |
| PE20091102A1 (es) | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
| WO2009095726A1 (en) * | 2008-01-29 | 2009-08-06 | Glenmark Pharmaceuticals, S.A. | Acrylamide derivatives as vanilloid receptor 1 modulators |
| JP5305704B2 (ja) * | 2008-03-24 | 2013-10-02 | 富士フイルム株式会社 | 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版 |
| US8250924B2 (en) | 2008-04-22 | 2012-08-28 | Rosemount Inc. | Industrial process device utilizing piezoelectric transducer |
| US8847571B2 (en) * | 2008-06-17 | 2014-09-30 | Rosemount Inc. | RF adapter for field device with variable voltage drop |
| CN102084307B (zh) | 2008-06-17 | 2014-10-29 | 罗斯蒙特公司 | 用于具有低压本质安全钳的现场设备的rf适配器 |
| US8929948B2 (en) | 2008-06-17 | 2015-01-06 | Rosemount Inc. | Wireless communication adapter for field devices |
| US8694060B2 (en) | 2008-06-17 | 2014-04-08 | Rosemount Inc. | Form factor and electromagnetic interference protection for process device wireless adapters |
| WO2010023512A1 (en) * | 2008-08-28 | 2010-03-04 | Matrix Laboratories Ltd. | Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them |
| CA2737775A1 (en) * | 2008-10-17 | 2010-04-22 | Abbott Laboratories | Trpv1 antagonists |
| US8604053B2 (en) * | 2008-10-17 | 2013-12-10 | Abbvie Inc. | TRPV1 antagonists |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| CN101654435B (zh) * | 2009-06-09 | 2014-01-29 | 沈阳药科大学 | N-苯甲基喹啉羧酸类化合物、组合物及其制备方法 |
| US20100318007A1 (en) * | 2009-06-10 | 2010-12-16 | O'brien Donald J | Electromechanical tactile stimulation devices and methods |
| US9674976B2 (en) | 2009-06-16 | 2017-06-06 | Rosemount Inc. | Wireless process communication adapter with improved encapsulation |
| US8626087B2 (en) | 2009-06-16 | 2014-01-07 | Rosemount Inc. | Wire harness for field devices used in a hazardous locations |
| US8648086B2 (en) | 2009-08-24 | 2014-02-11 | Ascepion Pharmaceuticals, Inc. | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors |
| US20120295942A1 (en) | 2010-02-01 | 2012-11-22 | Nicholas James Devereux | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| CN102753527B (zh) | 2010-02-02 | 2014-12-24 | 诺华股份有限公司 | 用作crf受体拮抗剂的环己基酰胺衍生物 |
| US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
| US10761524B2 (en) | 2010-08-12 | 2020-09-01 | Rosemount Inc. | Wireless adapter with process diagnostics |
| CN103635458B (zh) | 2011-03-25 | 2016-10-19 | 艾伯维公司 | Trpv1拮抗剂 |
| US9310794B2 (en) | 2011-10-27 | 2016-04-12 | Rosemount Inc. | Power supply for industrial process field device |
| US8859584B2 (en) | 2011-12-19 | 2014-10-14 | Abbvie, Inc. | TRPV1 antagonists |
| US8969325B2 (en) | 2011-12-19 | 2015-03-03 | Abbvie Inc. | TRPV1 antagonists |
| US8796328B2 (en) | 2012-06-20 | 2014-08-05 | Abbvie Inc. | TRPV1 antagonists |
| CN103739547B (zh) * | 2014-01-03 | 2015-09-02 | 沈阳药科大学 | 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法 |
| US9783527B2 (en) * | 2014-09-16 | 2017-10-10 | Abbvie Inc. | Indazole ureas and method of use |
| CN109574972A (zh) * | 2018-07-13 | 2019-04-05 | 郑州大学 | 一种3-烷基取代-4-色满酮类化合物及其制备方法 |
| US20240025856A1 (en) * | 2020-09-30 | 2024-01-25 | Katholieke Universiteit Leuven | 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer |
| WO2025161263A1 (zh) * | 2024-01-31 | 2025-08-07 | 深圳晶蛋生物医药科技有限公司 | 一种苯并吗啉类化合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8900565A (nl) | 1989-03-08 | 1990-10-01 | Philips Nv | Methode voor de verwerking van een radio data signaal, alsmede ontvanger voor de uitvoering van deze methode. |
| EP0386839B1 (en) * | 1989-03-08 | 1997-01-15 | Merck Sharp & Dohme Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| US5374643A (en) * | 1992-09-11 | 1994-12-20 | E. R. Squibb & Sons, Inc. | Aryl urea (thiourea) and cyanoguanidine derivatives |
| EP0922028A1 (en) * | 1996-08-26 | 1999-06-16 | Genetics Institute, Inc. | Inhibitors of phospholipase enzymes |
| CA2389360C (en) | 1999-11-16 | 2008-06-03 | Steffen Breitfelder | Urea derivatives as anti-inflammatory agents |
| CA2486092A1 (en) * | 2002-05-17 | 2003-11-27 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
| US7514562B2 (en) * | 2003-03-07 | 2009-04-07 | Glaxo Group Limited | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain |
| CN102161653A (zh) * | 2004-11-24 | 2011-08-24 | 雅培制药有限公司 | 抑制香草素受体亚型1(vr1)受体的苯并二氢吡喃基脲化合物及其用途 |
| KR20080067361A (ko) * | 2005-10-28 | 2008-07-18 | 아보트 러보러터리즈 | Ｔｒｐｖ1 수용체를 억제하는 인다졸 유도체 |
-
2005
- 2005-11-22 CN CN2011100508496A patent/CN102161653A/zh active Pending
- 2005-11-22 NZ NZ555318A patent/NZ555318A/en not_active IP Right Cessation
- 2005-11-22 JP JP2007543471A patent/JP4932730B2/ja not_active Expired - Fee Related
- 2005-11-22 EP EP05825417A patent/EP1844038A2/en not_active Withdrawn
- 2005-11-22 KR KR1020077014371A patent/KR101250824B1/ko not_active Expired - Fee Related
- 2005-11-22 BR BRPI0518581-5A patent/BRPI0518581A2/pt not_active IP Right Cessation
- 2005-11-22 EP EP12181173A patent/EP2527339A1/en not_active Withdrawn
- 2005-11-22 US US11/285,448 patent/US7812019B2/en not_active Expired - Fee Related
- 2005-11-22 CA CA002588909A patent/CA2588909A1/en not_active Abandoned
- 2005-11-22 WO PCT/US2005/042545 patent/WO2006065484A2/en not_active Ceased
- 2005-11-22 KR KR1020127028557A patent/KR20120137420A/ko not_active Withdrawn
- 2005-11-22 AU AU2005316972A patent/AU2005316972B2/en not_active Ceased
- 2005-11-22 CN CNA2005800467732A patent/CN101443327A/zh active Pending
- 2005-11-22 MX MX2007006205A patent/MX2007006205A/es active IP Right Grant
- 2005-11-24 TW TW094141323A patent/TW200633712A/zh unknown
-
2007
- 2007-05-20 IL IL183321A patent/IL183321A0/en unknown
-
2010
- 2010-09-03 US US12/875,839 patent/US8440691B2/en not_active Expired - Fee Related
-
2012
- 2012-01-11 JP JP2012003232A patent/JP2012111766A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008532925A5 (enExample) | ||
| JP3063162B2 (ja) | ベンズイミダゾール誘導体 | |
| CN1659144B (zh) | 喹啉和异喹啉衍生物、其制备方法以及作为炎症抑制剂的应用 | |
| JP4817020B2 (ja) | 置換フェニルカルコゲノ低級アルキル基とエステル構造を導入したフェニル基を置換基として有する新規１，２−ジヒドロキノリン誘導体 | |
| JP2008534511A5 (enExample) | ||
| AU2004238177B2 (en) | New benzimidazole derivatives | |
| JP2002522432A (ja) | 二置換二環式複素環化合物、それらの調製及び医薬組成物としてのそれらの使用 | |
| JP2009529496A (ja) | 誘導型一酸化窒素シンターゼ抑制剤として有用なキノロン類 | |
| JP2010523644A5 (enExample) | ||
| ZA200509632B (en) | Substituted hereroaryls as inhibitors of protein tyrosine phosphatases | |
| KR100395356B1 (ko) | 알파-2 아드레날린수용체 아고니스트로서 유용한 2-이미다졸리닐아미노인돌 화합물 | |
| CA2272640C (en) | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists | |
| WO2016104617A1 (ja) | キノリン誘導体 | |
| JP2008540574A5 (enExample) | ||
| WO2009061730A2 (en) | 4-heteroaryl-substituted phenoxyphenylacetic acid | |
| JP2010513298A (ja) | ベンゾイミダゾール系ｔｒｐｖ１阻害剤 | |
| JP2010500334A5 (enExample) | ||
| CN115286583B (zh) | 一种含二苯基氨基嘧啶类化合物、制备及其作为HDACs酶抑制剂的应用 | |
| RU2193562C2 (ru) | Производное 5-(2-имидазолиниламино)бензимидазола, фармацевтическая композиция | |
| CA2530312A1 (en) | Arylamine-substituted quinazolinone compounds | |
| JP2002525373A (ja) | ２−ピペラジノアルキルアミノベンゾアゾール誘導体：ドーパミン受容体サブタイプ特殊リガンド | |
| SK74999A3 (en) | 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists | |
| JP2010090117A (ja) | スルホン酸エステル構造を導入したフェニル基を置換基として有する新規１，２，３，４−テトラヒドロキノキサリン誘導体からなるグルココルチコイド受容体アゴニスト | |
| CN101033226B (zh) | 1-呋喃甲基-3-取代吲哚啉-2-酮衍生物 | |
| CA2241186C (en) | Benzimidazole derivatives |